6 unchanged sentences
The plaintiffs seek various damages, including punitive damages.
−Removed: In January 2022, the U.S.
−Removed: Judicial Panel on Multidistrict Litigation was asked to consolidate the federal court cases for pretrial purposes.
−Removed: In addition, on December 15, 2021, a purported class of Canadian preterm infants filed suit in British Columbia making similar allegations against Abbott.
+Added: In April 2022, the U.S.
+Added: Judicial Panel on Multidistrict Litigation ordered all federal court cases consolidated for pretrial purposes in the U.S.
+Added: District Court for the Northern District of Illinois.
+Added: In addition, in December 2021, a purported class of Canadian preterm infants filed suit in British Columbia and, in October 2022, a purported class of Israeli preterm infants filed suit in Tel Aviv, both of which make similar allegations as those made in the United States against Abbott.
These plaintiffs seek various damages, including punitive damages.
10 unchanged sentences
District Court for the District of Delaware alleging that DexCom breached the parties' 2014 Settlement and License Agreement by asserting infringement of patents against Abbott that DexCom previously licensed to Abbott.
+Added: In the U.S., DexCom’s patent infringement case is stayed pending resolution of Abbott’s breach of license case, which is currently set for trial on July 10, 2023.
+Added: Abbott’s U.S.
+Added: patent infringement trial against DexCom is currently scheduled for October 23, 2023.
+Added: In November 2022, Abbott learned that the United States Department of Justice, through the United States Attorney’s Office for the Western District of Michigan, is conducting a criminal investigation related to Abbott’s manufacturing of infant formula.
+Added: In December 2022, Abbott received a subpoena from the Enforcement Division of the Commission requesting information relating to Abbott’s powder infant formula business and related public disclosures.
+Added: In January 2023, Abbott received a civil investigative demand from the United States Federal Trade Commission seeking information in connection with its investigation of companies who participate in bids for Women, Infants, and Children infant formula contracts.
+Added: In addition, multiple civil lawsuits have been filed against Abbott regarding Abbott’s manufacturing of certain powder infant formula products.
MINE SAFETY DISCLOSURES
33 unchanged sentences
2017 to 2021 — Senior Vice President, International Nutrition.
−Removed: 2015 to 2017 — Vice President, Nutrition, Asia Pacific.
Elected Corporate Officer — 2015.
5 unchanged sentences
2017 to 2021 — Executive Vice President, Nutritional Products.
−Removed: 2014 to 2017 — Senior Vice President, Established Pharmaceuticals, Latin America.
Elected Corporate Officer — 2014.
5 unchanged sentences
2017 to 2020 —Vice President, Diagnostics, Commercial Operations, Europe, Middle East and Africa.
−Removed: 2012 to 2017 — Divisional Vice President, USA, Abbott Diagnostics Division.
Elected Corporate Officer — 2017.
2 unchanged sentences
2017 to 2021 — Vice President, Pediatric Nutrition.
−Removed: 2014 to 2017 — Divisional Vice President and General Manager, Pediatric Nutrition.
Elected Corporate Officer — 2017.
1 unchanged sentence
2017 to 2019 — Vice President, Structural Heart.
−Removed: 2016 to 2017 — Divisional Vice President and General Manager, Structural Heart.
−Removed: 2014 to 2016 — President and Chief Executive Officer, GI Dynamics, Inc.
−Removed: (a medical device company focused on developing gastrointestinal therapies).
Elected Corporate Officer — 2017.
4 unchanged sentences
Fernando Mateus, 48
−Removed: 2021 to present — Senior Vice President, International Nutrition.
+Added: 2021 to present — Senior Vice Pre sident, International Nutrition.
2018 to 2021 — Divisional Vice President, EURISA, Abbott International Nutrition.
2 unchanged sentences
Elected Corporate Officer — 202 1.
−Removed: 2021 to present — Senior Vice President, Rapid Diagnostics.
+Added: 2021 to present — Senior Vice Presi dent, Rapid Diagnostics.
2017 to 2021 — Vice President, Transfusion Medicine.
−Removed: 2015 to 2017 — Divisional Vice President and General Manager, Transfusion Medicine, ADD.
Elected Corporate Officer — 2017 .
−Removed: 2021 to present — Senior Vice President, Electrophysiology
+Added: 2021 to present — Senior Vice Pres ident, Electrophysiology.
2019 to 2021 — Senior Vice President, Electrophysiology and Heart Failure.
2017 to 2019 — Senior Vice President, Cardiac Arrhythmias and Heart Failure.
−Removed: 2015 to 2017 — Divisional Vice President and General Manager, Abbott Electrophysiology.
Elected Corporate Officer — 201 7.
−Removed: 2021 to present — Senior Vice President, Abbott Vascular.
+Added: 2021 to present — Senior Vice Pres ident, Abbott Vascular.
April 2021 to July 2021 — Divisional Vice President, U.S.
−Removed: Commercial, ADC.
−Removed: 2019 to 2021 — Divisional Vice President, Global Marketing, AVD.
+Added: Commercial, Abbott Diabetes Care.
+Added: 2019 to 2021 — Divisional Vice President, Global Marketing, Abbott Vascular.
2017 to 2019 — Divisional Vice President, U.S.
−Removed: Sales and Marketing Endovascular, AVD.
+Added: Sales and Marketing Endovascular, Abbott Vascular.
Elected Corporate Officer — 202 1.
−Removed: 2015 to present — Senior Vice President, Diabetes Care.
+Added: 2015 to present — Senior Vi ce President, Diabetes Care.
Elected Corporate Officer — 2015.
2017 to present — Senior Vice President, Established Pharmaceuticals, Latin America.
−Removed: 2014 to 2017 — General Manager, Argentina, Bolivia, Paraguay and Uruguay, Established Pharmaceuticals.
Elected Corporate Officer — 201 7.
Woodgrift, 61
−Removed: 2019 to present — Senior Vice President, CRM.
+Added: 2019 to present — Senior Vice Presid ent, Cardio Rhythm Management.
2017 to 2019 — Vice President, Global Operations, Cardiovascular and Neuromodulation.
−Removed: 2015 to 2017 — Vice President, Operations and R&D, Abbott Vascular.
Elected Corporate Officer — 2015 .
−Removed: 2020 to present — Vice President, Finance and Controller.
+Added: 2020 to present — Vice President, Finance a nd Controller.
2017 to 2020 — Divisional Vice President, Controller, Medical Devices.
−Removed: 2012 to 2017 — Divisional Vice President, Controller and Commercial Support, Point of Care.
Elected Corporate Officer — 2020 .
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.